ClinicalTrials.gg
Status unknownNCT05788913Updated Mar 29, 2023

Evaluation of the Pharmacodynamics of a Heparin With Its Biological Comparator, Subcutaneous Administration

A Phase 1 interventional study of Heparin in Anticoagulant, sponsored by Blau Farmaceutica S.A.. Status unknown. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-29.

Sponsored by Blau Farmaceutica S.A. · Phase 1, Interventional, and Other

How we know

The sponsor has not verified this record recently (last verified Mar 2023), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Experimental Drug: Porcine sodium heparin, injectable solution - 5,000 IU/ 0.25 mL; Blau Farmacêutica S/A.

Comparator Drug: Heparin Sodium Injection, USP, injectable solution - 5,000 IU/ 0.5 mL; Fresenius Kabi Lake Zurich.

Evaluate the equivalence in terms of pharmacodynamics of heparin sodium (test product) and Heparin Sodium Injection, USP (comparator product). The clinical trial will last approximately 08 weeks and the study population will consist of 68 healthy research participants, 34 women and 34 men

02

Conditions studied

  • Anticoagulant
03

In context

Lead sponsor

Blau Farmaceutica S.A. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide written approved by a Research Ethics Committee (CEP) prior to any trial-related activities;
  2. Healthy male or female participants between 18 and 55 years of age;
  3. Be in good health or have no significant illness at the discretion of the responsible researcher/physician, in accordance with what is defined in this protocol and the assessments to which he/she is submitted during recruitment and selection, such as: clinical history, vital signs, anthropometric data, physical examination , and laboratory tests;
  4. Have a (BMI) ≥ 18.5 and ≤ 29.9 Kg/m2, inclusive;
  5. Present body weight between 60 and 100 Kg;
  6. Agree to abstain from alcohol consumption for the duration of the study;
  7. Present a negative result for the test for detecting alcohol in urine or saliva;
  8. Test negative for the coronavirus (SARS-CoV-2);
  9. Be able to understand the nature and purpose of the study, including risks and adverse events;
  10. Act in accordance with the requirements of the entire trial, which is confirmed by signing the Free and Informed Consent Form (TCLE);
  11. The drug can bring serious risks to the fetus, so the research participant, whether female or male, must agree to use a safe method. Male participants must refrain from donating sperm from admission to final visit

Exclusion criteria

Exclusion Criteria:

  1. Present flu-like symptoms that, at the physician's discretion, are suspected of being infected by the coronavirus within 7 days prior to the period of hospitalization;
  2. Having had direct and significant contact at medical discretion with people who tested positive for the coronavirus (SARS-CoV-2) test within 14 days prior to the hospitalization period;
  3. Known to have a reaction to the studied drug, pork foods or chemically related compounds;
  4. Have used regular medication within 14 days prior to the hospitalization period;
  5. Have used any medication within 7 days prior to the hospitalization period, except for , cases in which, based on the half-life of the drug and/or active metabolites, complete elimination can be assumed or that, at the discretion of the responsible investigator/physician does not interfere in the pharmacokinetics or in the analytical stage of the study drug;
  6. Having received any vaccine dose within 7 days prior to the hospitalization period;
  7. Have received, within the three months prior to the study, treatment with any drug known to have well-defined toxic potential in large organs;
  8. Have participated in any experimental study or ingested any experimental drug within the six months prior to the start of this study;
  9. Have been hospitalized for any reason up to eight weeks before the start of the first treatment period of this study;
  10. Have a history of liver, gastrointestinal or other conditions that may interfere with the absorption, distribution, metabolism or excretion of the drug;
  11. Have a history of renal, respiratory, hematological, cardiological, neurological, neoplastic or psychiatric disease considered at the physician's discretion;
  12. Have a history of cardiac surgery (whatever), renal (renal exeresis or agenesis), gastrointestinal (partial or total removal of the esophagus, stomach, duodenum, jejunum, ileum, ascending colon, transverse colon, descending colon, sigmoid and rectum ) and surgery of the liver or pancreas;
  13. Have any current symptom or disease, acute or chronic, being monitored or treated, significant at the discretion of the responsible researcher/physician;
  14. Possess any active systemic or immunological disease or condition, including but not limited to the following general categories: cardiovascular/pulmonary, hepatic, renal or systemic infection or lactation;
  15. Electrocardiographic findings not recommended at the physician's discretion for participation in the study;
  16. Have the results of laboratory tests performed in the clinical evaluation of recruitment outside the values considered normal according to the reference values stipulated by the clinical analysis laboratory, unless they are considered not clinically significant by the researcher in charge/physician;
  17. Have results of laboratory tests that, according to medical evaluation, affect the safety of the research participant;
  18. Present clinically significant abnormalities on physical examination;
  19. Have donated blood in the last 30 days;
  20. Individuals taking aspirin or any other non-steroidal anti-inflammatory agent, with or without a doctor's prescription, within 10 days of treatment;
  21. Clinically significant abnormality in vital signs or (ECG), as judged by the investigator;
  22. Known allergic or undesirable reactions following the use of unfractionated heparin;
  23. Subjects who will undergo any surgical procedure within 14 days after the conclusion of the study;
  24. Failure to show up for the coronavirus (SARS-CoV-2) test before admission;
  25. Present a positive or inconclusive test for the coronavirus before admission;
  26. Present a positive test for pregnancy during pre-hospitalization;
  27. Present a positive result for the test for alcohol detection through urine or saliva;
  28. Have a positive preliminary drug test with methamphetamine, opiate/morphine, marijuana/tetrahydrocannabinol, amphetamine, cocaine/benzoylecgonine and/or benzodiazepine;
  29. Being a smoker or having quit smoking less than 6 months ago;
  30. Have a history of illicit drug abuse;
  31. Have an average alcohol intake of more than 3 alcoholic drinks in one day, or more than 7 alcoholic drinks per week, for women and more than 4 alcoholic drinks in one day, or more than 14 alcoholic drinks alcoholic beverages per week, for men;
  32. Have consumed alcohol and/or drugs in the 48 hours prior to the period of hospitalization;
  33. Having the habit of drinking more than five cups of coffee or tea a day;
  34. Ingest food or drinks containing xanthines in the 48 hours prior to hospitalization;
  35. Having done some intense physical exercise in the 48 hours prior to hospitalization;
  36. Having unusual eating habits or with restrictions at the discretion of the responsible researcher/physician;
  37. Be pregnant or breastfeeding, suspect pregnancy or wish to become pregnant while conducting the study;
  38. Have donated or lost 450 mL or more of blood in the last three months;
  39. Have donated or lost more than 1500 mL of blood in the last twelve months;
  40. Show inability to stay awake or lying down for 1 hour or time required at the doctor's discretion;
  41. Have any condition that prevents participation in the study at the discretion of the researcher in charge/physician;
  42. Research participant who has participated in clinical trial protocols in the last 12 (twelve) months (CNS Resolution 251, of August 7, 1997, item III, subitem J).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
68 participants (estimated)

Study arms

  • Active comparator
    Reference Drug

    Healthy participants using intravenous Heparin Sodium Injection, USP (Fresenius Kabi) to assess the pharmacodynamic profile

    Biological: Heparin

  • Experimental
    Test Drug

    Healthy participants using intravenous Heparin Test to assess the pharmacodynamic profile

    Biological: Heparin

Interventions

  • BiologicalHeparin

    subcutaneous Heparin

06

What researchers measure

Primary outcomes

  1. Evaluation of Amax parameter pharmacodynamics for the anti-FXA marker

    Amax: Maximum response, understood as the highest concentration, detected in plasma after treatment. The conclusion by the average equivalence is achieved when the confidence intervals 90% of the ratio of geometric averages of experimental and comparator drugs are between 80% and 125%.

    Time frame: 12 hours of blood collection from the administration of the test drug and 12 hours of blood collection from the administration of the reference drug. The doses will be separated by a minimum interval of 14 days.

  2. Evaluation of ASCE0-t parameter pharmacodynamics for the anti-FXA marker

    ASCE0-T: area under the effect-based effect curve versus time from zero to the last experimentally determined concentration; The conclusion by the average equivalence is achieved when the confidence intervals 90% of the ratio of geometric averages of experimental and comparator drugs are between 80% and 125%.

    Time frame: 12 hours of blood collection from the administration of the test drug and 12 hours of blood collection from the administration of the reference drug. The doses will be separated by a minimum interval of 14 days.

  3. Evaluation of ASCE0-inf parameter pharmacodynamics for the anti-FXA marker

    ASCE0-inf: Area under the effect curve based on concentration versus time from zero to infinity experimentally determined. The conclusion by the average equivalence is achieved when the confidence intervals 90% of the ratio of geometric averages of experimental and comparator drugs are between 80% and 125%.

    Time frame: 12 hours of blood collection from the administration of the test drug and 12 hours of blood collection from the administration of the reference drug. The doses will be separated by a minimum interval of 14 days.

  4. Evaluation of Amax parameter pharmacodynamics for the anti-FIIA marker

    Amax: Maximum response, understood as the highest concentration, detected in plasma after treatment. The conclusion by the average equivalence is achieved when the confidence intervals 90% of the ratio of geometric averages of experimental and comparator drugs are between 80% and 125%.

    Time frame: 12 hours of blood collection from the administration of the test drug and 12 hours of blood collection from the administration of the reference drug. The doses will be separated by a minimum interval of 14 days.

  5. Evaluation of ASCE0-t parameter pharmacodynamics for the anti-FIIA marker

    ASCE0-T: area under the effect-based effect curve versus time from zero to the last experimentally determined concentration; The conclusion by the average equivalence is achieved when the confidence intervals 90% of the ratio of geometric averages of experimental and comparator drugs are between 80% and 125%.

    Time frame: 12 hours of blood collection from the administration of the test drug and 12 hours of blood collection from the administration of the reference drug. The doses will be separated by a minimum interval of 14 days.

Secondary outcomes

  1. Sequence effects of pharmacodynamic parameters for the Anti-FXa marker - Analysis of variance (ANOVA)

    Amax and ASCEo-t and ASCEo-inf parameters will be analyzed by analyzing ANOVA variance to evaluate the sequence effects of the anti-fii marker

    Time frame: 12 hours of blood collection from the administration of the test drug and 12 hours of blood collection from the administration of the reference drug. The doses will be separated by a minimum interval of 14 days.

  2. Sequence effects of pharmacodynamic parameters for the Anti-FIIa marker - Analysis of variance (ANOVA)

    Amax and ASCEo-t parameters will be analyzed by analyzing ANOVA variance to evaluate the sequence effects of the anti-fii marker

    Time frame: 12 hours of blood collection from the administration of the test drug and 12 hours of blood collection from the administration of the reference drug. The doses will be separated by a minimum interval of 14 days.

  3. Ratio of Anti-FXa/Anti-FIIa activity based on the pharmacodynamic parameter ASCE0-t

    The ratio for anti-FXa/anti-FIIa activity of the ASCE0-t parameter will be evaluated. , the evaluation will be performed by comparing the interval of 90% of the ratio with the equivalence criterion 80% - 125%.

    Time frame: 12 hours of blood collection from the administration of the test drug and 12 hours of blood collection from the administration of the reference drug. The doses will be separated by a minimum interval of 14 days.

  4. Occurrence of adverse events and serious eventsevents

    Adverse events will be monitored for two months and reported in the final report. * Total of adverse events; * Total number of research participants who had adverse events; * Number of adverse events per period; * Number of adverse events due to causality; * Number of adverse events by type of medicine (formulation); * Number of adverse EA intensity events.

    Time frame: 2 months

  5. Evaluation of Amax parameter pharmacodynamics for the tissue factor pathway inhibitor (TFPI) activity

    TFPI serum concentrations will be quantified by ELISA method. will be evaluated by comparing the 90% interval for the ratios with the acceptance criteria 80% - 125%.

    Time frame: 12 hours of blood collection from the administration of the test drug and 12 hours of blood collection from the administration of the reference drug. The doses will be separated by a minimum interval of 14 days.

  6. Evaluation of ASCEo-t parameter pharmacodynamics for the tissue factor pathway inhibitor (TFPI) activity

    TFPI serum concentrations will be quantified by ELISA method. will be evaluated by comparing the 90% interval for the ratios with the acceptance criteria 80% - 125%.

    Time frame: 12 hours of blood collection from the administration of the test drug and 12 hours of blood collection from the administration of the reference drug. The doses will be separated by a minimum interval of 14 days.

  7. Evaluation of ASCEo-inf parameter pharmacodynamics for the tissue factor pathway inhibitor (TFPI) activity

    TFPI serum concentrations will be quantified by ELISA method. will be evaluated by comparing the 90% interval for the ratios with the acceptance criteria 80% - 125%.

    Time frame: 12 hours of blood collection from the administration of the test drug and 12 hours of blood collection from the administration of the reference drug. The doses will be separated by a minimum interval of 14 days.

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2023; primary completion for Jun 2023, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2023
First posted
Mar 29, 2023
StartEst.
Jun 1, 2023
Primary completionEst.
Jun 30, 2023
CompletionEst.
Sep 30, 2023
Last update
Mar 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05788913
Lead sponsor
Blau Farmaceutica S.A.
Responsible party
Sponsor
First posted
Mar 29, 2023
Start date
Jun 1, 2023 (estimated)
Primary completion
Jun 30, 2023 (estimated)
Completion
Sep 30, 2023 (estimated)
Last update
Mar 29, 2023

Study contacts

Blau Farmacêutica
Contact
pesquisaclinica@blau.com
114615-9400
Research Operations
Contact
Clinical Research
study director · Blau Farmaceutica S.A.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Heparin

Start the discussion